159 related articles for article (PubMed ID: 10828048)
1. Acquired DNA mutations associated with in vivo hydroxyurea exposure.
Hanft VN; Fruchtman SR; Pickens CV; Rosse WF; Howard TA; Ware RE
Blood; 2000 Jun; 95(11):3589-93. PubMed ID: 10828048
[TBL] [Abstract][Full Text] [Related]
2. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea for the treatment of sickle cell disease.
Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
[TBL] [Abstract][Full Text] [Related]
4. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
5. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.
Grigg A
Intern Med J; 2007 Mar; 37(3):190-2. PubMed ID: 17316339
[TBL] [Abstract][Full Text] [Related]
6. DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype.
da Silva Rocha LB; Dias Elias DB; Barbosa MC; Bandeira IC; Gonçalves RP
Mutat Res; 2012 Dec; 749(1-2):48-52. PubMed ID: 22918118
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
10. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.
Jones KM; Niaz MS; Brooks CM; Roberson SI; Aguinaga MP; Hills ER; Rice VM; Bourne P; Bruce D; Archibong AE
Int J Environ Res Public Health; 2009 Mar; 6(3):1124-44. PubMed ID: 19440437
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
13. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
[TBL] [Abstract][Full Text] [Related]
14. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
[TBL] [Abstract][Full Text] [Related]
15. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
[TBL] [Abstract][Full Text] [Related]
16. A systematic review on hydroxyurea therapy for sickle cell disease in India.
Pandey A; Kaur H; Borah S; Khargekar N; Karra VK; Adhikari T; Jain D; Madkaikar M
Indian J Med Res; 2022 Aug; 156(2):299-311. PubMed ID: 36629190
[TBL] [Abstract][Full Text] [Related]
17. Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation.
Adekile AD; Gupta R; Al-Khayat A; Mohammed A; Atyani S; Thomas D
Pediatr Blood Cancer; 2019 Feb; 66(2):e27503. PubMed ID: 30345708
[TBL] [Abstract][Full Text] [Related]
18. Two assays to evaluate potential genotoxic effects of hydroxyurea in sickle cell disease patients.
Rodríguez A; Kouegnigan L; Ferster A; Cotton F; Duez P
Hemoglobin; 2012; 36(6):545-54. PubMed ID: 23094637
[TBL] [Abstract][Full Text] [Related]
19. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease.
Haywood C; Beach MC; Bediako S; Carroll CP; Lattimer L; Jarrett D; Lanzkron S
Am J Hematol; 2011 Jan; 86(1):85-7. PubMed ID: 21117058
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]